This study tests whether adding a new high-intensity focused ultrasound device (Suizenji) to standard chemotherapy can help people with advanced pancreatic cancer that hasn't responded to first-line treatment. About 90 adults whose tumors can be seen on ultrasound will be randoml…
Phase: NA • Sponsor: SONIRE Therapeutics Inc. • Aim: Disease control
Last updated May 17, 2026 10:52 UTC